`Response to Restriction Requirement mailed July 19, 2023
`
`Attorney Docket No. 46682-7013 19
`
`
`
`This listing of claims replaces all prior versions and listing of claims in the above-
`
`referenced patent application. The following amendments do not constitute an admission
`
`regarding the patentability of the amended subject matter and should not be so construed.
`
`Amendments to the claims were made for purposes of more clearly stating the claimed subject
`
`matter and do not add new matter or alter the scope of the claims. Deletions are denoted by
`
`[strikethrough] and additions are denoted by underline.
`
`Listing of the Claims
`
`31.-48. (Canceled)
`
`49. (Withdrawn) An ophthalmic composition, comprising about 0.001 % w/vto about 0.05 %
`
`wiv atropine, sodium chloride, glycerin; chitosan; povidone; and water, at a pH of from
`
`about 3.8 to about 7.5.
`
`50. (Withdrawn) The ophthalmic composition of claim 49, comprising about 0.025 % wiv
`
`atropine.
`
`51. (Withdrawn) The ophthalmic composition of clairn 49, comprising about 0.01 % wiv
`
`atropine,
`
`52. (Withdrawn) The ophthalmic composition of claim 49, comprising about 0.05 % w/y
`
`atropine.
`
`33. (Withdrawn) The ophthalmic composition of claim 49, further comprising edetate
`
`disodium.
`
`54. (Withdrawn) The ophthalmic composition of claim 49, wherein the ophthalmic
`
`composition has a pH of about 5.5.
`
`ira) aH . (Withdrawn) The ophthalmic composition of claim 49, wherein the composition has a
`
`dose-to-dose ophthalmic concentration variation of less than 40%.
`
`Cas oN . Withdrawn) The ophthalmic composition of claim 49, wherein the ophthalmic
`
`composition comprises at least about 80%of the atropine based on initial concentration
`
`after extended period of time under storage condition.
`
`
`
`US. Serial No. 17/721,.831
`Response to Restriction Requirement mailed July 19, 2023
`
`Attorney Docket No. 46682-7013 19
`
`. (Withdrawn) The ophthalmic composition of claim 56, wherein the ophthalmic
`
`composition further has a potency of one ofat least 80%after extended period of time
`
`under storage condition.
`
`. Withdrawn) The ophthalmic composition of claim 56, wherein the storage condition has
`
`a storage temperature of from about 2°C to about 10°C or from about 16°C to about 26°C.
`
`.
`o
`a
`-
`oO
`oO
`_ {Previously Presented) A method oftreating myopia, comprisine administering an
`
`ophthalrnic composition to a subject in need thereof, wherein the ophthalmic composition
`
`comprises: about 0.001 % w/v to about 0.05 % w/v atropine; sodium chloride; glycerin:
`
`chitosan; povidone; and water, at a pH of from about 3.8 to about 7.5.
`
`60.
`
`(Previously Presented) The method of claim 59, comprising about 0.025 % w/vatropine.
`
`6l.
`
`‘Previously Presented) The method of claim 59, comprising about 0.01 %w/vatropine.
`.
`ow
`a
`2
`f
`
`2. (Previously Presented) The method of claim 59, comprising about 0.05 %w/v atropine.
`ae
`a
`
`. Previously Presented) The method of claim 59, further comprising edetate disodium.
`
`64.
`
`(Previously Presented) The method of claim 59, wherein the ophthalmic composition has
`
`a pHof about 5.5.
`
`65.
`
`(Previously Presented) The method of claim 59, wherein the cornpasition has a dose-to-
`
`dose ophthalmic concentration variation of less than 40%.
`
`66.
`
`(Previously Presented) The method of claim 59, wherein the ophthalmic composition
`
`comprises at least about 80°of the atropine based on inthal concentration after extended
`
`period of time under storage condition.
`
`. (Previously Presented) The method of claim 66, wherein the ophthalmic composition
`
`further bas a potency of one of: at least 80%after extended period of time under storage
`
`condition.
`
`O&.
`
`(Previously Presented) The method of claim 66, wherein the storage condition has a
`
`storage temperature of from about 2°C to about 10°C or from about 16°C to about 26°C.
`
`